Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.48 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.45 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.44 |
| ▸ | EHMT2 | Q96KQ7 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8936425 | 0.92 | ACHE (0.48) | ACHEBCHEROCK1MAP2K1POLB | |
| SCHEMBL8937943 | 0.90 | ROCK1 (0.56) | ACHEBCHEROCK1MAP2K1 | |
| SCHEMBL8935003 | 0.89 | MAP2K1 (0.57) | ACHEBCHEROCK1MAP2K1 | |
| SCHEMBL8936448 | 0.87 | ACHE (0.51) | ACHEBCHEMAP2K1POLB | |
| SCHEMBL13890346 | 0.85 | ROCK1 (0.53) | ACHEROCK1MAP2K1POLB | |
| SCHEMBL8938176 | 0.83 | MAP2K1 (0.55) | ACHEROCK1MAP2K1POLBMEN1 | |
| SCHEMBL8937994 | 0.83 | ROCK1 (0.55) | ACHEBCHEROCK1MAP2K1 | |
| SCHEMBL4013793 | 0.83 | ROCK1 (0.58) | ROCK1MEN1KMT2A | |
| SCHEMBL8934478 | 0.82 | ROCK1 (0.49) | ROCK1MAP2K1EHMT2 | |
| SCHEMBL8937945 | 0.82 | ROCK1 (0.56) | ROCK1MAP2K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188117-B2 | Piperidinyl-substituted isoquinolone derivatives | SANOFI-AVENTIS (FR) | 2012-05-29 | — | — | US | disclosed |
| US-20090093518-A1 | Piperidinyl-substituted isoquinolone derivatives | SANOFI-AVENTIS (FR) | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093518-A1 | Piperidinyl-substituted isoquinolone derivatives | MYLK2, MYLK, RHOT2 | ACHE 3559/4885BCHE 3883/4885NTSR1 4132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.